Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

tors presented positive results from Phase 2 clinical trials of Amigal at the American College of Medical Genetics (ACMG) meeting. The data showed that Amigal was generally safe and well-tolerated at all doses evaluated and no drug-related serious adverse events were reported. In addition, Amigal increased the level of the enzyme deficient in Fabry patients in 24 of 26 study subjects, and in a majority of study subjects the treatment resulted in a reduction of kidney GL-3 as measured in urine.

Amicus, along with its partner Shire, has initiated discussions with the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) regarding its plans for Phase 3 clinical evaluation of Amigal. Amicus expects to complete these interactions and provide an update in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate the Phase 3 clinical trial in the first half of 2009.

In parallel with the regulatory process, 23 of the original 26 patients continue to be treated with Amigal in the voluntary Phase 2 extension study to monitor long term safety and efficacy. In addition, the Company will evaluate modified doses and dose regimens in these 23 patients. Data from this extension study are expected to be available by Q1 2009, prior to finalization of the Phase 3 protocol.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic being developed for the treatment of Gaucher disease. At the ACMG meeting in March, clinical investigators presented full data from a 4 week Phase 2 study in Gaucher patients who switched from enzyme replacement therapy (ERT) with imiglucerase to the pharmacological chaperone Plicera. Results showed that Plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. In the trial, GCase activity, as measured in white blood cells, was increased in 20 of the 26 pat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched ... tinnitus. Patients listen to sound therapy that is tailor-made ... weeks to months, their tinnitus volume decreases. , AudioNotch has ... and Notched White Noise. Now, AudioNotch is pleased to announce ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... 2012 AtheroNova Inc. (OTCBB: AHRO), a biotech company ... regress atherosclerotic plaque, today announced that it has released ... company, no revenues were recognized in the twelve months ... for 2011 compared to $2,679,435 in 2010.  Net income ...
... 2012 Profil ® Institute for Clinical Research, Inc., ... and obesity, announced today its continued focus on contributing to ... on new therapies in diabetes in nine scientific journals last ... has authored two textbooks on drug therapy for type 2 ...
... Scientists are one step closer to making more complex microscopic ... "re-wire" DNA in yeast, according to research published today in ... Imperial College London, have demonstrated a way of creating a ... DNA and behave like wires in electronic circuitry. The scientists ...
Cached Biology Technology:AtheroNova Releases 2011 Financial Results 2AtheroNova Releases 2011 Financial Results 3Profil Institute Continues to Publish New Findings in Metabolic Research 2Scientists develop tools to make more complex biological machines from yeast 2
(Date:4/22/2014)... Fla. (April 21, 2014) -- There are all sorts ... feathers and spread their colorful tails; satin bowbirds build ... blue and shiny objects; and European bitterling males show ... has evolved a unique method to communicate with others. ... "Signaling can have profound fitness implications for ...
(Date:4/22/2014)... RIVERSIDE, Calif. Inspired by the fist-like club ... by University of California, Riverside, in collaboration with University ... design structure for composite materials that is more impact ... , "The more we study the club of this ... improve so many things we use every day," said ...
(Date:4/22/2014)... of nanotechnology researchers at the University of Kentucky has ... arrays using RNA. , The research, led by ... in Nanobiotechnology at the UK College of Pharmacy and ... "RNA as a Boiling-Resistant Anionic Polymer Material To Build ... Emil F. Khisamutdinov and Daniel L. Jasinski. , The ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2
... For the first time, researchers have confirmed an association ... and abnormalities on brain MRI, according to a new ... The new study raises the possibility that a toxic ... body long after administration. Brain MRI exams ...
... Peterhans, a Roosevelt University professor and adjunct curator at ... mammals in Africa, has announced the discovery of four ... of the Democratic Republic of Congo. , The mammals ... led by the Wildlife Conservation Society (WCS) and in ...
... of millions of Americans, there,s no such thing as the ... hear a constant ringing, buzzing, hissing, humming or other noise ... be debilitating and life-altering. Now, University of Michigan ... what is going on inside their unquiet brains. The ...
Cached Biology News:Contrast agent linked with brain abnormalities on MRI 2Chicago scientist involved in discovery of 4 new mammal species in Democratic Republic of Congo 2U-M tinnitus discovery opens door to possible new treatment avenues 2U-M tinnitus discovery opens door to possible new treatment avenues 3
nuclear RNA export factor 1, mRNA...
... of gene expression) technology allows ... profiles generated by SAGE are ... transcripts making it possible to ... Kit is designed to make ...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
...
Biology Products: